Effects of iloprost and factors affecting outcome in patients with severe inoperable lower limb ischaemia. U.K. Severe Limb Ischaemia Study Group.
The effects of i.v. iloprost given for 14-28 days on six month outcome in patients with severe inoperable lower limb ischaemia were investigated in a double-blind placebo controlled study. More iloprost patients (64%) survived with a viable limb than placebo patients (42%). Iloprost improved prognosis in all subgroups of patients, but patients with lower presenting ankle Doppler pressures had a worse outcome than patients with higher pressures.
Belcher
G
G
Cardiovascular Clinical Research Unit, Schering Health Care, West Sussex, U.K.
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016285:Iloprost / Q000627:therapeutic use*; D007511:Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000502:physiology
D016285:Iloprost